Back to Authors

Burnett, John C

0000-0002-3414-1659

Mayo Clinic

Cardiorenal Research Laboratory, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55905, USA.

Citations 2

Discovery of small molecule guanylyl cyclase B receptor positive allosteric modulators
Ma, Xiao , Peddibhotla, Satyamaheshwar , Zheng, Ye , Pan, Shuchong, Moroni, Dante , Chen, Qi-Yin, Ma, Xiaoyu , Burnett, John C. , Malany, Siobhan , Sangaralingham, S. Jeson , Moroni, Dante G , Chen, Qi-Yin , Ma, Xiaoyu , Burnett, John C , Malany, Siobhan , Sangaralingham, S. Jeson , Mehta, Alka

PNAS Nexus | June 6, 2024 | Volume: 3 | Issue: 6 | Pages: No page available

10.1093/pnasnexus/pgae225 Get It

Abstract Myocardial fibrosis is a pathological hallmark of cardiovascular disease (CVD), and excessive fibrosis can lead to new-onset heart failure and increased mortality. Currently, pharmacological therapies for myocardial fibrosis are limited, highlighting the need for novel therapeutic approaches. The particulate guanylyl cyclase B (GC-B) receptor possesses beneficial antifibrotic actions through the binding of its natural ligand C-type natriuretic peptide (CNP) and the generation of the intracellular second messenger, cyclic guanosine 3′,5′-monophosphate (cGMP). These actions include the suppression of fibroblast proliferation and reduction in collagen synthesis. With its abundant expression on fibroblasts, the GC-B receptor has emerged as a key molecular target for innovative CVD therapeutics. However, small molecules that can bind and potentiate the GC-B/cGMP pathway have yet to be discovered. From a cell-based high-throughput screening initiative of the NIH Molecular Libraries Small Molecule Repository and hit-to-lead evolution based on a series of structure–activity relationships, we report the successful discovery of MCUF-42, a GC-B-targeted small molecule that acts as a positive allosteric modulator (PAM). Studies herein support MCUF-42's ability to enhance the binding affinity between GC-B and CNP. Moreover, MCUF-42 potentiated cGMP levels induced by CNP in human cardiac fibroblasts (HCFs) and notably also enhanced the inhibitory effect of CNP on HCF proliferation. Together, our findings highlight that MCUF-42 is a small molecule that can modulate the GC-B/cGMP signaling pathway, potentially enhancing the antifibrotic actions of CNP. Thus, these data underscore the continued development of GC-B small molecule PAMs as a novel therapeutic strategy for targeting cardiac fibrosis and CVD.
Sex-based differences in metabolic protection by the ANP genetic variant rs5068 in the general population
Cannone, Valentina , Scott, Christopher G. , Sangaralingham, S. Jeson , Bailey, Kent R. , Goetze, Jens P. , Tsuji, Yoshihisa , Rodeheffer, Richard J. , Burnett, John C. , Ichiki, Tomoko , Cannone, Valentina , Scott, Christopher , Iyer, Seethalakshmi R., Burnett, John C , Iyer, Seethalakshmi , Sangaralingham, S. Jeson

American Journal of Physiology-Heart and Circulatory Physiology | July 7, 2023 | Volume: 325 | Issue: 3 | Pages: H545-H552

10.1152/ajpheart.00321.2023 Get It

Males are characterized by lower ANP and BNP with greater prevalence of cardiometabolic disease. The ANP genetic variant rs5068 was associated with less metabolic dysfunction in males, whereas no metabolic profile was related to the BNP genetic variant rs198389 in the general population. ANP may play a more biological role in metabolic homeostasis compared with BNP in the general population with greater physiological metabolic actions in males compared with females.